SecBot SecBot
SECBOTREPLAY Home › Report › IVVD

IVVD · Invivyd announced progress in its VYD2311 program for COVID-19…

Invivyd, Inc. · 8-K filed Apr 9, 2026 at 07:13 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Apr 9, 2026 at 07:13 ET

Invivyd announced progress in its VYD2311 program for COVID-19 prevention and the discovery of a new measles monoclonal antibody candidate, VMS063. The company provided updates on clinical trial advancements and pipeline progress.

  • Invivyd announced progress in its REVOLUTION program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention
  • The DECLARATION Phase 3 study for VYD2311 has been upsized by approximately 500 additional subjects
  • Top-line results for the DECLARATION study are now expected in Q3 2026, shifting from mid-year guidance
  • The company has aligned with the FDA on an initial pediatric study plan for VYD2311

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access